X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Lead Product(s): Cannabinoid-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Cannasoul
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2023
Details:
Bryostatin-1, a small molecule that works by activating protein kinase C, which is investigated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Cleveland Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 19, 2023
Details:
Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 18, 2022
Details:
Bryostatin 1 is a natural product derived from a marine microorganism called Bugula neritina, for patients suffering from advanced and moderately severe Alzheimer's disease.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) in the brain. PKC is an enzyme that plays an important role in maintaining the health of synapses, which are the connections between neurons (nerve cells).
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Preclinical studies have also demonstrated Bryostatin-1 regenerative mechanisms of action for the rare disease, as a treatment for Fragile X syndrome.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Bryostatin-1 caused highly significant cognitive enhancement for pre-specified patients who received Bryostatin-1 in absence of Namenda in our two previous, consolidated 3-month pilot trials, while the Placebo-treated patients showed no significant benefit.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Treatment with Bryostatin shown to increase blood vessel health, a key factor for prevention and disease reversal in patients suffering from Alzheimer's disease, The treatment not only stabilized decline, but importantly led to an increase in new micro-vessels.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
